STAT3 and lung adenocarcinoma: In lung adenocarcinoma, the low YTHDF1 group was mainly enriched in immunity-related signaling pathways (allograft rejection, IL6-JAK-STAT3 signaling, inflammatory response, and IL2-STAT5 signaling) (Table 4).